There are currently 49 active clinical trials seeking participants for Chronic Kidney Diseases research studies. The states with the highest number of trials for Chronic Kidney Diseases participants are California, Texas, Florida and New York.
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +99 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Register for Updates
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05719714
Recruiting
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
Register for Updates
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
07/22/2025
Locations: University of Arizona, Tucson, Arizona +77 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Register for Updates
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
NCT06110130
Recruiting
Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein. Secondary Objective: 1. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin... Read More
Gender:
ALL
Ages:
Between 19 years and 90 years
Trial Updated:
07/16/2025
Locations: Washington DC Veterans Affairs Medical Center (688), Washington, District of Columbia
Conditions: Chronic Kidney Diseases
Register for Updates
Concomitant Renal and Urinary Bladder Allograft Transplantation
NCT04626167
Recruiting
The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.
Gender:
ALL
Ages:
Between 1 year and 60 years
Trial Updated:
07/11/2025
Locations: Mayo Clinic, Rochester, Minnesota +1 locations
Conditions: Chronic Kidney Diseases, Bladder Dysfunction, Bladder Absence, Posterior Urethral Valve, Neurogenic Bladder, Bladder Exstrophy, Bladder Outlet Obstruction, Failure, Kidney, Transplant
Register for Updates
SPYRAL GEMINI Pilot Study
NCT06907147
Recruiting
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/10/2025
Locations: Piedmont Heart Institute, Atlanta, Georgia +7 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Register for Updates
Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
NCT06189807
Recruiting
This pilot study will assess the efficacy of a pregnancy and contraception education decision aid (DA) for patients with chronic kidney disease to support decisions about reproductive health, and will assess feasibility and acceptability of the intervention to inform future Research Project Grant (R01) level studies.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/24/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: CKD, Chronic Kidney Diseases
Register for Updates
Precision Medicine Approaches to Renal Osteodystrophy
NCT05880914
Recruiting
Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease patients and parathyroid hormone and bone alkaline phosphatase have insufficient accuracy for turnover type to safely and confidently guide treatment of renal osteodystrophy. In the present investigation, the investigators will study a microRNA approach as a novel non-invasi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Washington University in St. Louis (WashU), Saint Louis, Missouri
Conditions: Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Register for Updates
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
NCT03471117
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatme... Read More
Gender:
ALL
Ages:
Between 35 years and 70 years
Trial Updated:
06/07/2025
Locations: University of Texas at Arlington, Arlington, Texas +1 locations
Conditions: Chronic Kidney Diseases
Register for Updates
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
NCT06752577
Recruiting
The purpose of this treatment protocol is to treat an intermediate-sized population with chronic kidney disease (CKD). Protocol includes a single treatment with intravenously-delivered allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) infusion. Individuals will have subsequent follow up for safety evaluations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Chronic Kidney Diseases
Register for Updates
Sit Less, Interact and Move More (SLIMM) 2 Study
NCT05173714
Recruiting
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Theref... Read More
Gender:
ALL
Ages:
20 years and above
Trial Updated:
06/02/2025
Locations: Stanford University, Stanford, California +1 locations
Conditions: Chronic Kidney Diseases, Obesity
Register for Updates
A Long-Term Follow-Up Study of Participants Exposed to REACT
NCT05918523
Recruiting
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
05/27/2025
Locations: Boise Kidney & Hypertension Institute, Meridian, Idaho
Conditions: Diabetic Kidney Disease, Chronic Kidney Diseases
Register for Updates